Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its target price lowered by Robert W. Baird from $14.00 to $10.00 in a research report sent to investors on Friday, The Fly reports. A number of other research analysts have also issued reports on KPTI. HC Wainwright lowered their target price on Karyopharm Therapeutics from $16.00 to […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 17,760,000 shares, a decline of 7.0% from the March 31st total of 19,090,000 shares. Based on an average trading volume of 2,350,000 shares, the […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Equities researchers at Wedbush lifted their Q1 2023 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a research note issued on Wednesday, April 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.34) for the quarter, up […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily volume of 2,760,000 shares, the […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily trading volume, of 2,760,000 shares, […]